AU2566401A - 5-ht3 receptor antagonists for treatment of disorders involving airway constriction - Google Patents

5-ht3 receptor antagonists for treatment of disorders involving airway constriction

Info

Publication number
AU2566401A
AU2566401A AU2566401A AU2566401A AU2566401A AU 2566401 A AU2566401 A AU 2566401A AU 2566401 A AU2566401 A AU 2566401A AU 2566401 A AU2566401 A AU 2566401A AU 2566401 A AU2566401 A AU 2566401A
Authority
AU
Australia
Prior art keywords
treatment
receptor antagonists
disorders involving
ht3 receptor
airway constriction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2566401A
Inventor
Staffan Skogvall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respiratorius AB
Original Assignee
Respiratorius AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/SE2000/001267 priority Critical patent/WO2000076500A2/en
Application filed by Respiratorius AB filed Critical Respiratorius AB
Priority to PCT/SE2000/002613 priority patent/WO2001095903A1/en
Publication of AU2566401A publication Critical patent/AU2566401A/en
Application status is Pending legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
AU2566401A 1999-06-15 2000-12-20 5-ht3 receptor antagonists for treatment of disorders involving airway constriction Pending AU2566401A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/SE2000/001267 WO2000076500A2 (en) 1999-06-15 2000-06-15 Compound for use as a medicament for treatment of disorders involving bronchocontraction
PCT/SE2000/002613 WO2001095903A1 (en) 2000-06-15 2000-12-20 5-ht3 receptor antagonists for treatment of disorders involving airway constriction

Publications (1)

Publication Number Publication Date
AU2566401A true AU2566401A (en) 2001-12-24

Family

ID=20279203

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2566401A Pending AU2566401A (en) 1999-06-15 2000-12-20 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
AU2566301A Withdrawn AU2566301A (en) 1999-06-15 2000-12-20 A composition comprising a combination of receptor agonists and antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2566301A Withdrawn AU2566301A (en) 1999-06-15 2000-12-20 A composition comprising a combination of receptor agonists and antagonists

Country Status (2)

Country Link
AU (2) AU2566401A (en)
WO (2) WO2001095903A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
EP1625333A1 (en) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US20070179181A1 (en) * 2004-03-17 2007-08-02 Baxter Andrew D Treatment of inflammatory disorders and pain using beta-aminoalcohols
IN2013CH01199A (en) * 2013-03-20 2015-08-14 Suven Life Sciences Limited Quinoline compounds as 5-ht4 receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3872872T2 (en) * 1987-11-14 1993-02-04 Beecham Group Plc 5-HT3 receptor antagonists for treatment of cough and bronchoconstriction.
DK40890D0 (en) * 1990-02-16 1990-02-16 Ferrosan As Substituted urea compounds, their preparation and use
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
WO2000064441A2 (en) * 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
CN1355698A (en) * 1999-06-15 2002-06-26 呼吸器有限公司 Compound for medicine for treating function of bronchial contraction
GB9918425D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2001095902A1 (en) 2001-12-20
AU2566301A (en) 2001-12-24
WO2001095903A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
PL218221B1 (en) Preparation containing human antibodies for the treatment of disorders associated with TNF-α
PL366998A1 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
CZ20013061A3 (en) Use of sulfamate derivatives for treating disorders of pulse control
AU5914201A (en) Intrathecal administration of rituximab for treatment of central nervous system lymphomas
HK1059564A1 (en) Indanylderivatives for treating airway diseases
PL367272A1 (en) Novel substituted benzimidazole dosage forms and method of using same
ZA200408861B (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
HRP20040102A2 (en) Combinations for the treatment of inflammatory disorders
ZA200208674B (en) Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the NP Y5 receptor.
EP1311291A4 (en) Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
HK1061649A1 (en) N-(2-arylethyl) benzylamines as antagonists of the5-ht6 receptor
IL159344D0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
MXPA02001306A (en) Pharmaceutical compositions for the treatment of cns and other discorders.
IL151791D0 (en) Pharmaceutical composition for the treatment of respiratory diseases
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
EP1578988A4 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
SK1562004A3 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of diseases
HK1066790A1 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
WO1999017755A3 (en) Medicaments
AU2002329397A1 (en) Urea-compounds active as Vanilloid receptor antagonists for the treatment of pain
EP1827468A4 (en) Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer's disease
IL157734D0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
AU3661702A (en) Diagnosis of sleep breathing disorders
CZ20013023A3 (en) Monoamine reuptake inhibitors for treatment of central nervous system disorders
EP1482972A4 (en) Treatment of immunological disorders using anti-cd30 antibodies